Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TTPH
  • CUSIP: N/A
  • Web: www.tphase.com
Capitalization:
  • Market Cap: $280.49 million
  • Outstanding Shares: 37,956,000
Average Prices:
  • 50 Day Moving Avg: $7.94
  • 200 Day Moving Avg: $5.83
  • 52 Week Range: $3.11 - $9.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.24
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $4.67 million
  • Price / Sales: 60.06
  • Book Value: $3.15 per share
  • Price / Book: 2.35
Profitability:
  • EBIDTA: ($90,310,000.00)
  • Net Margins: -1,120.67%
  • Return on Equity: -39.95%
  • Return on Assets: -37.74%
Debt:
  • Current Ratio: 15.54%
  • Quick Ratio: 15.54%
Misc:
  • Average Volume: 625,723 shs.
  • Beta: 2.66
  • Short Ratio: 2.39
 

Frequently Asked Questions for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.20. The firm had revenue of $1.48 million for the quarter, compared to analysts' expectations of $1.46 million. Tetraphase Pharmaceuticals had a negative return on equity of 39.95% and a negative net margin of 1,120.67%. Tetraphase Pharmaceuticals's revenue was down 24.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.46) earnings per share. View Tetraphase Pharmaceuticals' Earnings History.

When will Tetraphase Pharmaceuticals make its next earnings announcement?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Tetraphase Pharmaceuticals.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued twelve-month target prices for Tetraphase Pharmaceuticals' shares. Their predictions range from $4.00 to $12.00. On average, they expect Tetraphase Pharmaceuticals' share price to reach $7.67 in the next year. View Analyst Ratings for Tetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 1,588,006 shares, an increase of 2.6% from the March 31st total of 1,547,868 shares. Based on an average daily trading volume, of 724,937 shares, the days-to-cover ratio is presently 2.2 days.

Who are some of Tetraphase Pharmaceuticals' key competitors?

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Canada Pension Plan Investment Board (4.46%), Vanguard Group Inc. (4.42%), Wellington Management Group LLP (4.02%), FMR LLC (3.72%), Tekla Capital Management LLC (2.71%) and Dimensional Fund Advisors LP (1.71%). Company insiders that own Tetraphase Pharmaceuticals stock include David Charles Lubner, Guy Macdonald, John Craig Thompson, L Patrick Gage and Patrick Taylor Horn. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.

Who sold Tetraphase Pharmaceuticals stock? Who is selling Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, Renaissance Technologies LLC, Candriam Luxembourg S.C.A., Wells Fargo & Company MN, Goldman Sachs Group Inc., Credit Suisse AG and Tudor Investment Corp ET AL. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., Acadian Asset Management LLC, Morgan Stanley, Geode Capital Management LLC, Bogle Investment Management L P DE and Nationwide Fund Advisors. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Tetraphase Pharmaceuticals stock cost?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $7.39.

Analyst Ratings

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $7.67 (3.74% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017BMO Capital MarketsReiterated RatingBuy$12.00LowView Rating Details
3/9/2017Stifel NicolausBoost Price TargetHold$5.00 -> $7.00LowView Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00N/AView Rating Details
5/16/2016GabelliReiterated RatingNeutralN/AView Rating Details
5/14/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
11/19/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$12.00 -> $21.00N/AView Rating Details
9/9/2015GuggenheimLower Price TargetBuy$60.00 -> $20.00N/AView Rating Details
9/9/2015Robert W. BairdDowngradeOutperform -> Neutral$41.00 -> $10.00N/AView Rating Details
9/9/2015Cantor FitzgeraldDowngradeBuy -> Hold$50.00 -> $11.00N/AView Rating Details
9/9/2015NomuraDowngradeBuy -> Neutral$54.00 -> $10.00N/AView Rating Details
9/9/2015Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
9/9/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Earnings History by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/2/2017Q1 2017($0.60)($0.79)$1.46 million$1.48 millionViewN/AView Earnings Details
3/8/2017Q4($0.60)($0.61)$1.28 million$1.09 millionViewListenView Earnings Details
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)$2.74 million$3.07 millionViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
2017 EPS Consensus Estimate: ($2.41)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.56)($0.59)
Q2 20172($0.63)($0.58)($0.61)
Q3 20172($0.65)($0.59)($0.62)
Q4 20172($0.65)($0.53)($0.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 55.63%
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2017L Patrick GageDirectorBuy11,000$7.49$82,390.00View SEC Filing  
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Source:
DateHeadline
globenewswire.com logoTetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017 - GlobeNewswire (press release)
globenewswire.com - May 22 at 8:26 AM
finance.yahoo.com logoTetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017
finance.yahoo.com - May 22 at 8:26 AM
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : May 15, 2017
finance.yahoo.com - May 15 at 7:31 PM
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : May 12, 2017
finance.yahoo.com - May 12 at 3:32 PM
americanbankingnews.com logoZacks Investment Research Lowers Tetraphase Pharmaceuticals Inc (TTPH) to Sell
www.americanbankingnews.com - May 10 at 8:54 AM
americanbankingnews.com logoBMO Capital Markets Reaffirms "Buy" Rating for Tetraphase Pharmaceuticals Inc (TTPH)
www.americanbankingnews.com - May 6 at 4:32 PM
finance.yahoo.com logoTetraphase reports 1Q loss
finance.yahoo.com - May 5 at 8:01 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights
finance.yahoo.com - May 5 at 12:57 AM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Issues Quarterly Earnings Results, Misses Estimates By $0.19 EPS
www.americanbankingnews.com - May 4 at 11:24 PM
americanbankingnews.com logoZacks: Brokerages Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Post Quarterly Sales of $1.69 Million
www.americanbankingnews.com - May 3 at 1:38 PM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 2 at 10:31 AM
americanbankingnews.com logoZacks: Brokerages Expect Tetraphase Pharmaceuticals Inc (TTPH) to Announce -$0.61 EPS
www.americanbankingnews.com - May 1 at 9:04 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Affect Tetraphase Pharmaceuticals (TTPH) Share Price
www.americanbankingnews.com - May 1 at 7:14 PM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Short Interest Update
www.americanbankingnews.com - May 1 at 4:58 PM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) to Release Earnings on Tuesday
www.americanbankingnews.com - April 30 at 8:36 AM
americanbankingnews.com logoTetraphase Pharmaceuticals (TTPH) Given Media Impact Score of 0.50
www.americanbankingnews.com - April 28 at 11:50 AM
americanbankingnews.com logoTetraphase Pharmaceuticals (TTPH) Receiving Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 25 at 4:35 PM
streetinsider.com logoTetraphase Pharma (TTPH) to Present Data at ECCMID
www.streetinsider.com - April 22 at 7:31 PM
nasdaq.com logoImplied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options - Nasdaq
www.nasdaq.com - April 22 at 11:07 AM
streetinsider.com logoTetraphase Pharma (TTPH) to Present Data at ECCMID - StreetInsider.com
www.streetinsider.com - April 22 at 11:07 AM
finance.yahoo.com logoTetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
finance.yahoo.com - April 21 at 10:33 AM
finance.yahoo.com logoImplied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options
finance.yahoo.com - April 21 at 10:33 AM
americanbankingnews.com logoTetraphase Pharmaceuticals (TTPH) Earning Somewhat Negative Media Coverage, Study Shows
www.americanbankingnews.com - April 21 at 7:53 AM
americanbankingnews.com logoTetraphase Pharmaceuticals (TTPH) Given Coverage Optimism Rating of -0.06
www.americanbankingnews.com - April 14 at 3:10 PM
americanbankingnews.com logo Analysts Anticipate Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - April 10 at 2:28 PM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 9:10 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
finance.yahoo.com - April 3 at 8:12 PM
streetinsider.com logoTetraphase Pharma (TTPH) TP-6076 Awarded $4M in Research Funding by CARB-X - StreetInsider.com
www.streetinsider.com - April 1 at 7:32 AM
bizjournals.com logo​These 5 Mass. biotechs are getting $12M to fight ‘superbugs’
www.bizjournals.com - April 1 at 7:32 AM
streetinsider.com logoTetraphase Pharma (TTPH) TP-6076 Awarded $4M in Research Funding by CARB-X
www.streetinsider.com - March 31 at 5:04 AM
finance.yahoo.com logo4:01 pm Tetraphase Pharmaceuticals announces that its pipeline candidate TP-6076 was selected to receive $4 mln in research funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
finance.yahoo.com - March 31 at 5:04 AM
finance.yahoo.com logoTetraphase Pharmaceuticals’ TP-6076 Selected by CARB-X to Receive $4 Million in Research Funding
finance.yahoo.com - March 31 at 5:04 AM
globenewswire.com logoTetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 27 at 7:34 PM
finance.yahoo.com logoTetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 27 at 8:34 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Tetraphase (TTPH) Stock?
finance.yahoo.com - March 21 at 9:48 AM
finance.yahoo.com logoTETRAPHASE PHARMACEUTICALS INC Financials
finance.yahoo.com - March 18 at 2:27 AM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Director Buys $82,390.00 in Stock
www.americanbankingnews.com - March 16 at 8:27 PM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 14 at 4:25 PM
biz.yahoo.com logoTETRAPHASE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 7:57 PM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Stock Rating Upgraded by BMO Capital Markets
www.americanbankingnews.com - March 10 at 2:45 PM
fool.com logoTetraphase Pharmaceuticals Inc Is Climbing Again Today -- Here's Why
www.fool.com - March 10 at 12:19 PM
biz.yahoo.com logoQ4 2016 Tetraphase Pharmaceuticals Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 9 at 3:27 AM
us.rd.yahoo.com logoTetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones
us.rd.yahoo.com - March 9 at 3:27 AM
biz.yahoo.com logoTETRAPHASE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
us.rd.yahoo.com - March 9 at 3:27 AM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 9 at 1:27 AM
globenewswire.com logoTetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 6 at 11:59 AM
finance.yahoo.com logoTetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 6 at 11:59 AM
feeds.benzinga.com logoTetraphase Pharmaceuticals to Host Conference Call on March 8 to Discuss Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
feeds.benzinga.com - March 3 at 8:22 AM
thestreet.com logoFirst Week Of August 18th Options Trading For Tetraphase Pharmaceuticals (TTPH)
www.thestreet.com - February 15 at 6:40 AM
investopedia.com logoTetraphase Says Antibiotic Has Strong Sales Prospects
www.investopedia.com - February 14 at 6:41 AM

Social

Chart

Tetraphase Pharmaceuticals (TTPH) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff